Evidence map›Paper›PMID 36651182›Full record

ArticleACS infectious diseases2023

Re-sensitization of Multidrug-Resistant and Colistin-Resistant Gram-Negative Bacteria to Colistin by Povarov/Doebner-Derived Compounds.

Kenneth I Onyedibe, Ansley M Nemeth, Neetu Dayal, Richard D Smith, Jones Lamptey, Robert K Ernst, Roberta J Melander, Christian Melander, Herman O Sintim

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kenneth I OnyedibeDepartment of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana47907, United States.
Ansley M NemethDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana46556, United States.
Neetu DayalDepartment of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana47907, United States.ORCID 0000-0002-2705-7061
Richard D SmithDepartment of Microbial Pathogenesis, University of Maryland-Baltimore, Baltimore, Maryland21201, United States.
Jones LampteyDepartment of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana47907, United States.
Robert K ErnstDepartment of Microbial Pathogenesis, University of Maryland-Baltimore, Baltimore, Maryland21201, United States.
Roberta J MelanderDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana46556, United States.
Christian MelanderDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana46556, United States.ORCID 0000-0001-8271-4696
Herman O SintimDepartment of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana47907, United States.ORCID 0000-0002-2280-9359
Purdue University West Lafayette · USUniversity of Notre Dame · USUniversity of Maryland, Baltimore · US

Funding

Colistin-resistant Acinetobacter baumanniiR01AI104895 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI, ERNST, ROBERT K · 2014 to 2024
$4.2M
Development of Antibiotic Adjuvants for Gram-Negative BacteriaR01AI136904 · NIAID · UNIVERSITY OF NOTRE DAME · PI MELANDER, CHRISTIAN COREY · 2018 to 2022
$3.7M
MS Diagnostic Bacterial Identification LibraryR01AI147314 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI ERNST, ROBERT K, GOODLETT, DAVID ROBINSON · 2020 to 2024
$2.3M
NIAID NIH HHS R01 AI104895NIAID NIH HHS R01 AI136904NIAID NIH HHS R01 AI147314
6 · The paper itself

Abstract

Colistin, typically viewed as the antibiotic of last resort to treat infections caused by multidrug-resistant (MDR) Gram-negative bacteria, had fallen out of favor due to toxicity issues. The recent increase in clinical usage of colistin has resulted in colistin-resistant isolates becoming more common. To counter this threat, we have investigated previously reported compounds,

Indexed as

Anti-Bacterial AgentsColistinGram-Negative BacteriaBacteriaDrug Resistance, Multiple, BacterialEscherichia coliPseudomonas aeruginosaReactive Oxygen SpeciesAnti-Bacterial AgentsColistinReactive Oxygen Speciesantibiotic potentiationcolistin-resistant bacteriaGram-negativemultidrug-resistant

Identifiers

PMID36651182
PMCPMC10547215
OpenAlexW4317359835

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.